Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  • End date
    May 30, 2025
  • participants needed
  • sponsor
Updated on 22 October 2021
Amgen Call Center
Primary Contact
Brampton Clinical Trials (1.7 mi away) Contact
+1350 other location
myocardial infarction
arterial disease


This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

Condition Coronary Artery Disease, Coronary heart disease, Ischemic Heart Disease, Cardiac Ischemia, Myocardial Ischemia, coronary disease, disease, coronary, coronary heart diseases
Treatment Placebo, Evolocumab
Clinical Study IdentifierNCT03872401
Last Modified on22 October 2021


Yes No Not Sure

Inclusion Criteria

Age: Adult subjects 50 (men) or 55 (women) to 80 years of age (either sex) and meeting lipid criteria
Low-density lipoprotein cholesterol (LDL-C) 90 mg/dL ( 2.3 mmol/L) or non-high-density lipoprotein cholesterol (non-HDL) 120 mg/dL ( 3.1 mmol/L), or apolipoprotein B 80 mg/dL ( 1.56 mol/L)
Evidence of at least one of the following at screening (without prior myocardial infarction or stroke)
Significant coronary artery disease (CAD) B. Significant atherosclerotic cerebrovascular disease C. Significant peripheral arterial disease D. Diabetes mellitus
At least 1 high-risk feature

Exclusion Criteria

MI or stroke prior to randomization
Coronary artery bypass grafting (CABG) 3 months prior to screening
Estimated glomerular filtration rate (eGFR) 15 mL/min/1.73 m
Uncontrolled or recurrent ventricular tachycardia in the absence of an implantable-cardioverter defibrillator
Atrial fibrillation or atrial flutter not on anticoagulation therapy (vitamin K antagonist, heparin, low molecular weight heparin, fondaparinux,or non-Vitamin K antagonist oral anticoagulant)
Triglycerides 500 mg/dL (5.7 mmol/L) measured up to 3 months prior to screening. The most recent results must be used
Last measured left-ventricular ejection fraction 30% or New York Heart Association (NYHA) Functional Class III/IV
Planned arterial revascularization
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note